ArticleJAMA internal medicine2018
Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
Article in JAMA internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review.PharmacoEconomics · 2019Pooled it
- Epidemiologic and economic impact of introducing a National Immunization Program for herpes zoster vaccination on the prevention of herpes zoster and postherpetic neuralgia in South Korea, an ageing society.Epidemiology and infection · 2026Article
- Article
- Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China.PharmacoEconomics - open · 2025Article
- The recombinant shingles vaccine is associated with lower risk of dementia.Nature medicine · 2024Article
- Article
- Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.Human vaccines & immunotherapeutics · 2023Review
- Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States.PharmacoEconomics - open · 2023Article
- Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Article
- Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review.Preventive medicine reports · 2022Review
- Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults.Dermatology and therapy · 2022Article
- Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.PharmacoEconomics · 2022Article
- Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review.Therapeutic advances in vaccines and immunotherapy · 2022Review
- Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.Human vaccines & immunotherapeutics · 2021Article
- Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.Human vaccines & immunotherapeutics · 2021Article
- Estimated Public Health Impact of the Recombinant Zoster Vaccine.Mayo Clinic proceedings. Innovations, quality & outcomes · 2021Article
- Vaccination for quality of life: herpes-zoster vaccines.Aging clinical and experimental research · 2021Review
- Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.PloS one · 2021Article
- The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.Human vaccines & immunotherapeutics · 2020Article
- Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.Applied health economics and health policy · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The live attenuated herpes zoster vaccine (ZVL) is recommended for immunocompetent adults 60 years or older, but the efficacy wanes with age and over time. A new adjuvanted herpes zoster subunit vaccine (HZ/su) has higher efficacy but might be more expensive. The choice of vaccines depends on their relative values. Objective: To assess the cost-effectiveness of HZ/su. Design, Setting, and Participants: Markov decision model with transition probabilities based on the US medical literature. Participants were immunocompetent adults 60 years or older. Data were derived from participant groups ranging in number from less than 100 to more than 30 000 depending on the variable assessed. The study dates were July 1 to 31, 2017. Exposures: No vaccination, ZVL (single dose), and HZ/su (2-dose series) vaccine administered at different ages. Main Outcomes and Measures: Total costs and quality-adjusted life-years (QALYs) were estimated. Results: Based on randomized clinical trial data, at a price of $280 per series ($140 per dose), HZ/su was more effective and less expensive than ZVL at all ages. The incremental cost-effectiveness ratios compared with no vaccination ranged from $20 038 to $30 084 per QALY, depending on vaccination age. The finding was insensitive to variations in most model inputs other than the vaccine price and certain combinations of low adherence rate with a second dose and low efficacy of a single dose of HZ/su. At the current ZVL price ($213 per dose), HZ/su had lower overall costs than ZVL up to a price of $350 per 2-dose series. In probabilistic sensitivity analysis, HZ/su had 73% probability of being cost-effective for 60-year-olds at $50 000 per QALY. Conclusions and Relevance: Under conservative assumptions, at a price of $280 per series ($140 per dose), HZ/su would cost less than ZVL and has a high probability of offering good value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.